A number of other research analysts have also weighed in on OMCL. Zacks Investment Research lowered shares of Omnicell from a hold rating to a sell rating in a research report on Friday, February 15th. ValuEngine raised shares of Omnicell from a buy rating to a strong-buy rating in a research report on Friday, March 1st. Dougherty & Co raised their price target on shares of Omnicell from $78.00 to $90.00 and gave the company a buy rating in a research report on Thursday, March 7th. Craig Hallum lowered shares of Omnicell from a buy rating to a hold rating and set a $84.00 price target on the stock. in a research report on Friday, April 26th. Finally, Benchmark raised their price target on shares of Omnicell from $82.00 to $90.00 and gave the company a buy rating in a research report on Friday, April 26th. Five investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Omnicell presently has a consensus rating of Buy and a consensus target price of $79.89.
OMCL opened at $83.52 on Tuesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.47 and a current ratio of 1.96. Omnicell has a fifty-two week low of $49.45 and a fifty-two week high of $86.87. The stock has a market cap of $3.44 billion, a P/E ratio of 54.59, a PEG ratio of 2.60 and a beta of 1.14.
In other Omnicell news, EVP Nhat H. Ngo sold 1,823 shares of Omnicell stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $82.33, for a total value of $150,087.59. Following the sale, the executive vice president now owns 37,569 shares of the company’s stock, valued at $3,093,055.77. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Chairman Randall A. Lipps sold 65,161 shares of Omnicell stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $63.77, for a total transaction of $4,155,316.97. The disclosure for this sale can be found here. In the last ninety days, insiders sold 131,224 shares of company stock worth $9,469,511. Insiders own 2.77% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the business. Parallel Advisors LLC bought a new stake in shares of Omnicell in the first quarter valued at approximately $28,000. Bronfman E.L. Rothschild L.P. raised its position in shares of Omnicell by 451.8% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 618 shares of the company’s stock valued at $38,000 after purchasing an additional 506 shares during the period. C M Bidwell & Associates Ltd. bought a new stake in shares of Omnicell in the first quarter valued at approximately $42,000. Nisa Investment Advisors LLC raised its position in shares of Omnicell by 125.0% in the first quarter. Nisa Investment Advisors LLC now owns 540 shares of the company’s stock valued at $44,000 after purchasing an additional 300 shares during the period. Finally, IFP Advisors Inc raised its position in shares of Omnicell by 109.3% in the fourth quarter. IFP Advisors Inc now owns 741 shares of the company’s stock valued at $45,000 after purchasing an additional 387 shares during the period. 97.32% of the stock is currently owned by institutional investors and hedge funds.
Omnicell Company Profile
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Further Reading: Growth and Income Funds
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.